Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2004 1
2005 3
2006 3
2007 9
2008 18
2009 11
2010 11
2011 8
2012 8
2013 3
2014 3
2015 6
2016 12
2017 12
2018 10
2019 6
2020 10
2021 8
2022 11
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, Bhattacharjee A, Swain M, Mathrudev V, Nawale K, Balaji A, Peelay Z, Alone M, Pathak S, Mahajan A, Kumar S, Purandare N, Agarwal A, Puranik A, Pendse S, Reddy Yallala M, Sahu H, Kapu V, Dey S, Choudhary J, Krishna MR, Shetty A, Karuvandan N, Ravind R, Rai R, Jobanputra K, Chaturvedi P, Pai PS, Chaukar D, Nair S, Thiagarajan S, Prabhash K. Patil VM, et al. Among authors: budrukkar a. J Clin Oncol. 2023 May 1;41(13):2350-2361. doi: 10.1200/JCO.22.00980. Epub 2023 Jan 27. J Clin Oncol. 2023. PMID: 36706347 Clinical Trial.
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Noronha V, et al. Among authors: budrukkar a. J Clin Oncol. 2018 Apr 10;36(11):1064-1072. doi: 10.1200/JCO.2017.74.9457. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220295 Clinical Trial.
Function Preservation with Brachytherapy: Reviving the Art.
Rembielak A, Budrukkar A, Kron T. Rembielak A, et al. Among authors: budrukkar a. Clin Oncol (R Coll Radiol). 2023 Aug;35(8):485-488. doi: 10.1016/j.clon.2023.06.010. Epub 2023 Jun 20. Clin Oncol (R Coll Radiol). 2023. PMID: 37394265 No abstract available.
In Regard to Steenbakkers et al.
Kashid S, Swain M, Budrukkar A, Ghosh-Laskar S. Kashid S, et al. Among authors: budrukkar a. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):903. doi: 10.1016/j.ijrobp.2022.02.026. Int J Radiat Oncol Biol Phys. 2022. PMID: 35772445 No abstract available.
Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity.
Laskar SG, Chaukar D, Deshpande M, Chatterjee A, Sinha S, Chakraborty S, Agarwal JP, Gupta T, Budrukkar A, Murthy V, Pai P, Chaturvedi P, Pantvaidya G, Deshmukh A, Nair D, Nair S, Prabhash K, Swain M, Kumar A, Noronha V, Patil V, Joshi A, DCruz A. Laskar SG, et al. Among authors: budrukkar a. Eur J Cancer. 2023 Mar;181:179-187. doi: 10.1016/j.ejca.2022.12.016. Epub 2022 Dec 26. Eur J Cancer. 2023. PMID: 36669426 Clinical Trial.
Factors influencing cosmetic outcome in breast conservation.
Munshi A, Kakkar S, Bhutani R, Jalali R, Budrukkar A, Dinshaw KA. Munshi A, et al. Among authors: budrukkar a. Clin Oncol (R Coll Radiol). 2009 May;21(4):285-93. doi: 10.1016/j.clon.2009.02.001. Epub 2009 Feb 27. Clin Oncol (R Coll Radiol). 2009. PMID: 19249195 Review.
The MUSES∗: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment: ∗MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers.
Ferrari M, Mattavelli D, Tomasoni M, Raffetti E, Bossi P, Schreiber A, Orlandi E, Taboni S, Rampinelli V, Gualtieri T, Turri-Zanoni M, Battaglia P, Arosio AD, Bignami M, Tartaro T, Molteni M, Bertazzoni G, Fiaux-Camous D, Jourdaine C, Verillaud B, Eu D, Nair D, Moiyadi A, Shetty P, Ghosh-Laskar S, Budrukkar A, Magrini SM, Guillerm S, Faivre S, Piazza C, Gilbert RW, Irish JC, de Almeida JR, Pai P, Herman P, Castelnuovo P, Nicolai P. Ferrari M, et al. Among authors: budrukkar a. Eur J Cancer. 2022 Aug;171:161-182. doi: 10.1016/j.ejca.2022.05.010. Epub 2022 Jun 17. Eur J Cancer. 2022. PMID: 35724468 Free article.
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K. Patil VM, et al. Among authors: budrukkar a. Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31. Cancer. 2019. PMID: 31150120 Free article. Clinical Trial.
143 results